FDA advisers backed Grail’s Galleri multicancer blood test, voting that probable benefits outweigh risks, while still expressing concerns about effectiveness and the consequences of false reassurance. The molecular and clinical genetics panel voted 7-2 in favor, with one abstention, in a session focused on safety and clinical utility. Debate centered on whether Galleri could lead patients to forgo guideline-recommended screening when no cancer signal is detected. Panelists also discussed the need to contextualize follow-up testing risk, including the balance of false positives versus the clinical exposure from additional diagnostics. The FDA follows advisory panel input in most cases, and the vote provides a decision signal ahead of a possible approval for the methylation-based liquid biopsy under the agency’s premarket pathway.